HUMANIZED ANTI-IL-20 ANTIBODY AND USES THEREOF

Ming-Shi Chang (Inventor)

Research output: Patent

Abstract

The present disclosure provides humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure.
Original languageEnglish
Patent number9217031
Publication statusPublished - 1800

Fingerprint

Antibodies, Monoclonal, Humanized
Antibodies
Disclosure
Osteoporosis
Renal Insufficiency
Rheumatoid Arthritis
Stroke
Neoplasms
interleukin 20

Cite this

@misc{0728fd5e53824873918dd59617241835,
title = "HUMANIZED ANTI-IL-20 ANTIBODY AND USES THEREOF",
abstract = "The present disclosure provides humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure.",
author = "Ming-Shi Chang",
year = "1800",
language = "English",
type = "Patent",
note = "9217031",

}

TY - PAT

T1 - HUMANIZED ANTI-IL-20 ANTIBODY AND USES THEREOF

AU - Chang, Ming-Shi

PY - 1800

Y1 - 1800

N2 - The present disclosure provides humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure.

AB - The present disclosure provides humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure.

M3 - Patent

M1 - 9217031

ER -